According to VistaGen Therapeutics latest financial reports the cash on hand of VTGN is $16.64M, an decrease of -75.58% to 2022. At the end of 2022 company had $68.14M cash on hand. This amount reflects the liquid assets available to the company, which are crucial for its operational flexibility, investment opportunities, and overall financial security.
Year | Cash on Hand | Change |
---|---|---|
2023 | $16.64M | -75.58% |
2022 | $68.14M | -33.92% |
2021 | $103.11M | 7508.91% |
2020 | $1.36M | -89.66% |
2019 | $13.10M | - |